Clinigen Group Plc (NASDAQ:CLIGF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Wednesday, May 24th.
According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “
Shares of Clinigen Group Plc (NASDAQ:CLIGF) remained flat at $9.96 during mid-day trading on Wednesday. The firm has a market cap of $1.14 billion and a price-to-earnings ratio of 62.25. Clinigen Group Plc has a 12-month low of $7.36 and a 12-month high of $10.05.
TRADEMARK VIOLATION WARNING: This report was first reported by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/06/16/clinigen-group-plc-cligf-downgraded-by-zacks-investment-research-to-hold-updated-updated.html.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.